70261-81-3

Basic information

• Product Name: 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE
• Synonyms: 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE;1-Methyl-4-(4-nitrobenzyl)piperazine95%;1-METHYL-4-[(4-NITROPHENYL)METHYL]-PIPERAZINE DIHYDROCHLORIDE;1-Methyl-4-[(4-nitrophenyl)Methyl]piperazine;1-(4-Methyl-3-nitrobenzyl)-4-Methylpiperazine
• CAS NO: 70261-81-3
• Molecular Formula: C₁₂H₁₇N₃O₂
• Molecular Weight: 235.28
• EINECS: 201-215-5
• Product Categories: API intermediates
• Mol File: 70261-81-3.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 358.2 °C at 760 mmHg
• Flash Point: 170.4 °C
• Appearance: /
• Density: 1.184 g/cm³
• PKA: 7.51±0.10(Predicted)
• CAS DataBase Reference: 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE(70261-81-3)
• EPA Substance Registry System: 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE(70261-81-3)

Safety Data

• Hazardous Substances Data: 70261-81-3(Hazardous Substances Data)

Usage

General Description

1-METHYL-4-(4-NITROBENZYL)PIPERAZINE is a chemical compound with the molecular formula C12H17N3O2. It is a piperazine derivative with a methyl group and a 4-nitrobenzyl group attached to the piperazine ring. 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE has been studied for its potential pharmacological properties, including its role as a potential antipsychotic agent. It is also used in the synthesis of various pharmaceuticals and may have other industrial applications. 1-METHYL-4-(4-NITROBENZYL)PIPERAZINE should be handled and used with care due to its potential health hazards and toxicity.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 99-99-0 1-methyl-4-nitrobenzene 
• 555-16-8 4-nitrobenzaldehdye 
• 1015484-22-6 1-methyl-4-((trifluoro-λ⁴-boranyl)methyl)piperazine potassium 
• 586-78-7 para-nitrophenyl bromide 
• 100-00-5 4-chlorobenzonitrile 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Downstream Products

• 916739-34-9 4-[(4-methyl-1-piperazinyl)methyl]phenylamine trihydrochloride 
• 1350443-64-9 4-(1H-imidazol-1-yl)-N-[4-(4-methylpiperazin-1-ylmethyl)phenyl]benzamide 
• 1350443-65-0 N-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-4-[(quinolin-5-yl)amino]benzamide 
• 1350443-66-1 N-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-4-[(2-methylquinolin-5-yl)amino]benzamide 
• 1429515-59-2 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide 

Relevant articles and documents

(4 - Fused heterocycle-substituted amino)-3 - 1H-pyrazolecarboxamide compound and application thereof

The invention relates to the field of pharmaceutical chemistry and in particular relates to 4-(fused-heterocycle substituted amino)-1H-pyrazol-3-formamide compounds and application thereof, preparation methods of the compounds, pharmaceutical compositions

BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

Discovery of the selective and efficacious inhibitors of FLT3 mutations

Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy. Starting from the lead compound LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivatives were synthesized to improve the FLT3 inhibitory potency and selectivity. Among them, compound 50 was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib. Compound 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants. Inversely, compound 50 displayed no cytotoxicity to FLT3-independent cells, and the biochemical analyses showed that its effects were related to the inhibition of FLT3 signal pathways. Additionally, compound 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry. Moreover, compound 50 showed enhanced metabolic stability. Altogether, it was concluded that compound 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.